In recent years, few regulatory topics have attracted as much attention as endocrine disruptors, chemicals capable of interfering with hormone systems in humans and wildlife. Their potential effects on development, reproduction, and environmental health have prompted increasingly rigorous scrutiny across the globe.

Discover Cehtrawatch, the digital regulatory monitoring tool that keeps your business compliant with controlled updates and no software installation needed.

ECHA developed in 2022 a recommended (i.e. not mandatory) framework guidance to applicants for approval of biocidal active substances but also to Member State Competent Authorities (MSCAs) on how to perform an analysis of alternatives (AoA) to active substances being candidate for substitution (CfS) according to Art. 10(1) of the Biocidal Products Regulation ((EU) 528/2012). The guidance has been adopted at BPC-45 meeting and published in January 2023.

On 2nd of December 2021, the ECHA Biocidal Products Committee (BPC) recommended the approval of ABDAC/BKC and adopted the BPC opinion for PT2 by simple majority. Two Member States (Germany and Finland) raised their concerns about unacceptable risk for environment, mainly for the soil compartment.

In the recent meeting of Coordination Group (CG-54), a proposal of the Austrian Member State was discussed which has been raised in a CG e-consultation, concerning information on the use frequency of products (“Number and timing of application”) for use in PT 1, PT2 and PT4 given by the applicants in SPC and PAR for BPR product authorization.